Enabling Clinical-Grade Automated Manufacturing Of γδ T Cells

Emerging γδ T cell therapies are pushing the boundaries of cell-based immunotherapy, but their unique biology requires equally specialized manufacturing strategies. Gain practical insight into building scalable workflows tailored to Vδ2 T cells, from automated, GMP-compliant expansion to efficient genetic modification using BaEV-pseudotyped lentiviral vectors. Explore how integrated platforms can reduce hands-on time while improving consistency, and how advanced flow cytometry supports robust analytical testing and streamlined process validation. Whether refining an existing workflow or establishing a new pipeline, these approaches offer a clearer path toward reproducible, clinically relevant γδ T cell production.

Dive deeper to uncover strategies that can accelerate development and de-risk your process.